KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to -$8.2 million.

  • Royalty Pharma's Other Non Operating Income fell 27322.98% to -$8.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$14.4 million, marking a year-over-year decrease of 83913.61%. This contributed to the annual value of -$14.3 million for FY2025, which is 83907.07% down from last year.
  • Latest data reveals that Royalty Pharma reported Other Non Operating Income of -$8.2 million as of Q4 2025, which was down 27322.98% from -$1.6 million recorded in Q3 2025.
  • Royalty Pharma's 5-year Other Non Operating Income high stood at $6.0 million for Q2 2024, and its period low was -$18.3 million during Q4 2023.
  • Moreover, its 5-year median value for Other Non Operating Income was -$1.7 million (2023), whereas its average is -$2.9 million.
  • In the last 5 years, Royalty Pharma's Other Non Operating Income tumbled by 418604.65% in 2022 and then skyrocketed by 44995.42% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Other Non Operating Income stood at -$4.8 million in 2021, then soared by 75.83% to -$1.2 million in 2022, then crashed by 1471.5% to -$18.3 million in 2023, then soared by 88.04% to -$2.2 million in 2024, then plummeted by 273.23% to -$8.2 million in 2025.
  • Its last three reported values are -$8.2 million in Q4 2025, -$1.6 million for Q3 2025, and -$1.5 million during Q2 2025.